NASDAQ:FGEN
FibroGen Stock News
$1.20
-0.0400 (-3.23%)
At Close: May 17, 2024
Astellas Pharma : Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia | MarketScreener
02:34pm, Tuesday, 09'th Jun 2020FibroGen Initiates Phase II/III Study in Severe Coronavirus
02:17pm, Tuesday, 09'th Jun 2020
FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.
FibroGen Announces New Roxadustat Data Presented At 2020 ERA-EDTA Virtual Congress
09:01pm, Monday, 08'th Jun 2020FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress | MarketScreener
09:01pm, Monday, 08'th Jun 2020FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress
09:00pm, Monday, 08'th Jun 2020
Roxadustat demonstrates non-inferiority to darbepoetin alfa in achievement of Hb correction in DOLOMITES Phase 3 study of anemia in non-dialysis dependent patients with chronic.
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
11:00am, Monday, 08'th Jun 2020
FibroGen, Inc. (FGEN) today announced the initiation of an open-label, randomized, parallel-arm study investigating the efficacy and safety of pamrevlumab versus standard of care in patients with seve
FibroGen Inc (NASDAQ: FGEN) Q1 2020 Earnings Call Transcript | AlphaStreet
06:01pm, Tuesday, 02'nd Jun 2020
Final earnings conference call transcript of FibroGen Inc. - FGEN stock
Akebia Therapeutics: A Clear Path To A Blockbuster CKD-Anemia Treatment (NASDAQ:AKBA)
02:13am, Monday, 01'st Jun 2020
Akebia has taken a significant step towards securing approval for Vadadustat, its potential blockbuster treatment for anemia in CKD sufferers. Data from the pha
FibroGen to Present at Upcoming Investor Conferences | MarketScreener
11:01am, Wednesday, 27'th May 2020FibroGen to Present at Upcoming Investor Conferences
11:00am, Wednesday, 27'th May 2020
SAN FRANCISCO, May 27, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following.
European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat
11:00am, Thursday, 21'st May 2020
TOKYO and SAN FRANCISCO, May 21, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique.
